CT Findings of Lymphangioleiomyomatosis: A Case of Pneumothorax and Renal Angiomyolipoma
What is the key CT finding of lymphangioleiomyomatosis?
The characteristic CT pattern of lymphangioleiomyomatosis is numerous bilateral, round, thin-walled pulmonary cysts distributed diffusely throughout both lungs. Pneumothorax and renal angiomyolipoma are important associated findings that can strengthen the diagnostic impression.
Executive Answer
Lymphangioleiomyomatosis (LAM) should be considered when a woman presents with acute pleuritic chest pain or dyspnea and chest CT demonstrates numerous bilateral, round, thin-walled cysts distributed diffusely throughout the lungs. In this case, a large right pneumothorax was the acute finding, while the diffuse cystic lung pattern provided the key diagnostic clue. A small hyperechoic lesion in the lower pole of the left kidney was also most consistent with a renal angiomyolipoma, an important extrapulmonary association of LAM. Recognizing the combination of diffuse cystic lung disease, pneumothorax, and renal angiomyolipoma can substantially narrow the differential diagnosis.
Why This Case Matters
Lymphangioleiomyomatosis is an uncommon cystic lung disease that can initially present through an acute complication rather than through a previously established chronic pulmonary diagnosis.
The important radiologic lesson is that the acute abnormality—in this case, a large right pneumothorax—should not distract the reader from the underlying lung pattern.
The chest CT demonstrates two findings that should be interpreted together:
A large right pneumothorax
Multiple small, round, thin-walled cysts distributed throughout both lungs
The renal ultrasound adds another clinically meaningful clue: a 1-cm hyperechoic lesion in the lower pole of the left kidney that most closely resembles an angiomyolipoma.
This combination makes LAM the leading diagnosis in the presented case.
Clinical Scenario
A woman in her early 40s presented with acute pleuritic chest pain and shortness of breath.
A noncontrast chest CT was obtained for evaluation.
The CT demonstrated a large right pneumothorax. No left pneumothorax was identified. In addition, numerous cysts measuring less than 1 cm were distributed relatively evenly throughout both lungs. There was no substantial pleural effusion.
Additional retroperitoneal evaluation with ultrasound demonstrated a 1-cm hyperechoic lesion at the lower pole of the left kidney. The lesion was considered most consistent with a renal angiomyolipoma. The remainder of the left kidney was described as normal in size and echogenicity.
Imaging Findings
Chest CT
The dominant acute finding is a large right pneumothorax.
The more important diagnostic clue, however, is the underlying cystic lung pattern. The cysts are:
Small
Round
Thin-walled
Relatively uniform in appearance
Diffusely distributed throughout both lungs
The intervening lung parenchyma is not described as substantially abnormal.
This pattern is characteristic of LAM and differs from several other diffuse cystic lung diseases in which cyst distribution, morphology, or associated parenchymal abnormalities provide important distinguishing clues.
Figure 1. Axial lung-window CT demonstrating a large right pneumothorax and numerous small, round, thin-walled cysts distributed throughout the lungs.
Figure 2. Coronal lung-window CT demonstrating the diffuse distribution of thin-walled pulmonary cysts.
Renal Ultrasound
Ultrasound demonstrated a 1-cm hyperechoic lesion at the lower pole of the left kidney.
The lesion most closely resembles an angiomyolipoma.
In the context of diffuse cystic lung disease, recognition of a renal angiomyolipoma is particularly important because it provides an extrapulmonary clue supporting LAM.
Figure 3. Left renal ultrasound demonstrating a small hyperechoic lesion at the lower pole of the kidney.
Figure 4. Additional left renal ultrasound image demonstrating the same hyperechoic lesion.
Radiologist's Reasoning
The diagnostic reasoning can be organized around three observations:
1. A woman with acute respiratory symptoms
The clinical presentation is acute, with pleuritic chest pain and dyspnea.
2. A large pneumothorax
LAM is associated with recurrent pneumothorax because progressive cystic destruction of the lung creates vulnerable areas that can rupture.
3. Diffuse, bilateral, thin-walled cysts
This is the key imaging clue. The cysts are small, round, thin-walled, and distributed throughout both lungs rather than being concentrated in a single region.
The renal lesion then provides an additional clue.
The combination of diffuse cystic lung disease, pneumothorax, and a renal lesion compatible with angiomyolipoma strongly supports LAM.
Why the Finding Can Be Missed
The acute pneumothorax may dominate attention during interpretation of an emergency chest CT.
This creates a potential satisfaction-of-search problem: once the immediate cause of dyspnea and chest pain has been identified, the underlying diffuse lung abnormality may receive less attention.
A systematic review of the entire lung parenchyma is therefore important even when an obvious emergency finding is present.
The diagnostic question should not stop at:
Why is this patient short of breath?
It should also ask:
Why did this pneumothorax occur, and what does the underlying lung architecture show?
That second question is particularly important when the CT demonstrates diffuse cystic change.
Differential Diagnosis of Diffuse Cystic Lung Disease
The case lists several important alternatives:
Lymphangioleiomyomatosis
Birt-Hogg-Dubé syndrome
Pulmonary Langerhans cell histiocytosis
Light chain deposition disease
Emphysema
Lymphangioleiomyomatosis
LAM classically produces numerous bilateral, relatively uniform, round, thin-walled cysts with diffuse distribution.
The cysts can involve the lungs extensively while the intervening lung parenchyma remains relatively preserved.
Pneumothorax and chylous pleural effusion are recognized complications or associated findings.
Renal angiomyolipoma is another important extrapulmonary association.
Birt-Hogg-Dubé Syndrome
Birt-Hogg-Dubé syndrome is another important cause of diffuse cystic lung disease and pneumothorax.
The distinction requires attention to cyst morphology and distribution as well as the clinical and family history. Renal tumors and characteristic skin findings can provide additional clues.
Pulmonary Langerhans Cell Histiocytosis
Pulmonary Langerhans cell histiocytosis can produce cystic lung disease, but the distribution and morphology of the cysts differ from the classic diffuse, relatively uniform pattern of LAM.
An upper-lung predominance and characteristic nodular and cystic evolution are important considerations.
Light Chain Deposition Disease
Light chain deposition disease can produce cystic pulmonary abnormalities but is substantially less characteristic of the classic LAM pattern.
Clinical context and associated systemic findings are important when considering this diagnosis.
Emphysema
Emphysema produces areas of low attenuation rather than true, discrete, thin-walled cysts.
Recognizing the presence or absence of definable cyst walls is therefore important when differentiating emphysema from cystic lung disease.
Diagnostic Algorithm
A practical imaging-oriented approach is:
A key principle is to avoid diagnosing a diffuse cystic lung disease from a single imaging feature in isolation. The overall pattern and associated clinical findings should be considered together.
Clinical Significance of Renal Angiomyolipoma
The renal ultrasound finding is more than an incidental abdominal observation.
A hyperechoic renal lesion is compatible with angiomyolipoma, particularly when it demonstrates the expected imaging characteristics. In this case, the lesion is approximately 1 cm and located at the lower pole of the left kidney.
When diffuse cystic lung disease is present, identification of a renal angiomyolipoma can provide an important diagnostic clue toward LAM.
This illustrates a broader radiology principle:
A finding outside the primary field of clinical concern can become the key to interpreting the primary imaging abnormality.
The chest CT establishes the pattern of diffuse cystic lung disease, while the renal finding strengthens the clinical-radiologic connection.
LAM: Pathophysiologic Context
LAM is a rare cystic lung disease characterized by abnormal proliferation of neoplastic smooth-muscle-like LAM cells.
The disease can cause progressive cystic destruction of the lung and involve the lymphatic system. Abdominal tumors or other extrapulmonary manifestations may also occur.
The underlying molecular biology involves abnormalities affecting the tuberous sclerosis complex pathway, including TSC1 and TSC2 and downstream mechanistic target of rapamycin (mTOR) signaling.
LAM predominantly affects women, particularly during the reproductive years.
The clinical course can vary considerably between patients.
Clinical Manifestations
The clinical manifestations of LAM may include:
Dyspnea
Cough
Chest pain
Fatigue
Chylothorax
Chylous ascites
Hemoptysis
Recurrent pneumothorax
The presentation may therefore range from chronic respiratory symptoms to an acute emergency caused by pneumothorax.
This variability is one reason imaging recognition is important.
Imaging Pattern of LAM
Chest Radiograph
Potential radiographic findings include:
Diffuse cystic change
Increased interstitial reticular markings
Pneumothorax
Pleural effusion
High-Resolution CT
High-resolution CT is particularly important for characterizing the pulmonary cyst pattern.
The classic imaging appearance consists of numerous thin-walled cysts distributed throughout the lungs.
The cysts may vary in size, and the source case describes a range of approximately 2 to 20 mm in the discussion section.
The intervening lung parenchyma may appear relatively normal.
Associated findings can include:
Pneumothorax
Chylous pleural effusion
Renal angiomyolipoma
Other lymphatic or abdominal manifestations
The distribution and morphology of the cysts are more diagnostically useful than simply counting the number of cysts.
Diagnostic Risk: The Emergency Finding Can Hide the Chronic Disease
This case illustrates a common radiology risk pattern:
Acute abnormality → immediate clinical action → reduced attention to background disease
A large pneumothorax appropriately demands attention. However, once the pneumothorax is identified, the remaining lung should still be reviewed systematically.
The diffuse cystic pattern changes the interpretation of the pneumothorax.
Rather than viewing the pneumothorax as an isolated event, the radiologist should consider whether an underlying diffuse cystic lung disease explains the patient's vulnerability to pneumothorax.
This is a practical example of why complete field-of-view review matters in emergency imaging.
AI Perspective
AI can potentially assist radiologists in cases of diffuse cystic lung disease by functioning as a detection or second-reader tool.
Potential applications include:
Flagging diffuse cystic abnormalities
Supporting detection of pneumothorax
Quantifying cyst burden
Identifying unexpected abnormalities outside the primary clinical target
Supporting structured characterization of lung abnormalities
However, these are potential workflow applications rather than claims about the performance of any specific commercial system.
No AI performance data are provided in this case.
The important principle is that AI should support, rather than replace, radiologist interpretation.
Where AI Could Help—and Where It Could Fail
A future AI workflow could potentially identify a combination of:
Pneumothorax + diffuse pulmonary cysts + renal abnormality
That combination could prompt the radiologist to consider an underlying cystic lung disease such as LAM.
However, several limitations must be recognized.
False Negatives
An AI system may fail to recognize small cysts, particularly when image quality is limited or when the cysts are subtle.
False Positives
Paraseptal emphysema, bullae, artifacts, and other low-attenuation abnormalities could potentially be misclassified as cystic disease.
Domain Shift
An algorithm trained on one patient population or CT acquisition environment may not generalize perfectly to other institutions, scanners, reconstruction techniques, or patient populations.
Unexpected Pathology
AI systems may perform poorly when multiple abnormalities coexist or when the clinically important diagnosis depends on integrating findings across different organs and modalities.
Automation Bias
A radiologist should not assume that an AI output is correct simply because it is presented with high confidence.
The clinician remains responsible for verifying the actual CT findings, their distribution, and their clinical significance.
Healthcare Workflow Implications
This case also demonstrates the value of cross-modality reasoning.
The initial chest CT identifies the characteristic pulmonary pattern. Subsequent renal ultrasound provides an additional clue.
In an enterprise imaging environment, clinically meaningful information may therefore be distributed across:
CT → PACS → Radiologist → Ultrasound → EHR/EMR → Clinical Decision Support
The value of an imaging finding is not limited to the modality on which it was first detected.
A well-integrated workflow should allow relevant prior and contemporaneous imaging findings to be reviewed together.
For AI-enabled systems, this creates an important challenge: detecting a pulmonary pattern on CT is one task; connecting it with a renal angiomyolipoma detected on ultrasound is a broader multimodality reasoning problem.
That distinction matters when evaluating medical imaging AI.
Practical Radiology Pearls
Diffuse, bilateral, round, thin-walled pulmonary cysts should immediately raise consideration of LAM in an appropriate clinical context.
A pneumothorax may be the acute presentation of an underlying diffuse cystic lung disease.
Do not stop reviewing the lungs after identifying the pneumothorax.
Cyst distribution is diagnostically important. Diffuse and relatively uniform involvement favors LAM over several other cystic lung diseases.
A renal angiomyolipoma can provide an important extrapulmonary clue to LAM.
A hyperechoic renal lesion should be characterized in context rather than dismissed as an incidental finding.
Birt-Hogg-Dubé syndrome, pulmonary Langerhans cell histiocytosis, light chain deposition disease, and emphysema should remain in the differential diagnosis of diffuse cystic lung disease.
The intervening lung parenchyma can help distinguish LAM from other cystic or lucent lung disorders.
The complete imaging pattern is more informative than any single cyst.
AI may support detection and prioritization, but it does not eliminate diagnostic responsibility.
Common Diagnostic Pitfalls
1. Stopping after identifying the pneumothorax
The pneumothorax explains the acute symptoms but not necessarily the underlying cause.
2. Calling every low-attenuation area a cyst
True cysts have definable walls. Emphysematous lucencies do not have the same morphology.
3. Ignoring cyst distribution
The spatial distribution of cysts is a major component of the differential diagnosis.
4. Missing extrapulmonary clues
Renal angiomyolipoma may be diagnostically valuable in the appropriate setting.
5. Anchoring on the emergency finding
A dramatic acute abnormality can reduce attention to chronic or background disease.
6. Treating an AI output as a diagnosis
AI-generated detections require human verification.
7. Assuming that a typical CT pattern eliminates the need for clinical correlation
Diffuse cystic lung disease has multiple causes. The imaging pattern must be interpreted together with the patient's clinical and extrapulmonary findings.
FAQ
What is the key CT finding in lymphangioleiomyomatosis?
The key finding is multiple bilateral, round, thin-walled pulmonary cysts distributed diffusely throughout the lungs. The intervening lung parenchyma may appear relatively preserved.
Why is pneumothorax important in LAM?
Pneumothorax is a recognized clinical manifestation of LAM and may be the event that leads to the initial diagnosis of the underlying diffuse cystic lung disease.
Is renal angiomyolipoma associated with LAM?
Yes. Renal angiomyolipoma is an important extrapulmonary association of LAM and can provide a useful diagnostic clue when diffuse cystic lung disease is present.
What are the major imaging differentials for diffuse cystic lung disease?
Important considerations include LAM, Birt-Hogg-Dubé syndrome, pulmonary Langerhans cell histiocytosis, light chain deposition disease, and emphysema. Cyst morphology, distribution, clinical history, and associated findings help distinguish these entities.
Can LAM cause chylous pleural effusion?
Yes. Chylous pleural effusion, or chylothorax, is a recognized manifestation associated with LAM.
What is the role of CT in LAM?
CT, particularly high-resolution CT, is central to characterizing the morphology and distribution of pulmonary cysts and identifying associated thoracic abnormalities such as pneumothorax and pleural effusion.
Can AI help identify LAM?
AI could potentially support detection of diffuse cystic lung abnormalities, pneumothorax, or other imaging features. However, the performance of any specific AI system must be established independently, and AI output requires radiologist verification.
Does this case establish a diagnosis from CT alone?
The case presents LAM as the diagnosis based on the characteristic imaging pattern together with a renal lesion compatible with angiomyolipoma. In real-world practice, definitive diagnosis should be established through appropriate clinical-radiologic correlation and additional testing when necessary.
Educational Quiz
Question 1
Which CT pattern best supports lymphangioleiomyomatosis?
A. Large, irregular cysts predominantly confined to one lung
B. Small, round, relatively uniform cysts distributed throughout both lungs
C. Upper-lung-predominant thin-walled cysts
D. Centrilobular lucencies without definable walls
Answer: B. The characteristic pattern of LAM consists of multiple bilateral, round, thin-walled cysts with diffuse distribution.
Question 2
Which extrapulmonary finding in this case supports LAM?
A. Fibrofolliculomas
B. Lymphoma
C. Renal angiomyolipoma
D. Dermatomyositis
Answer: C. A renal angiomyolipoma is an important extrapulmonary association of LAM.
Question 3
Which acute complication is demonstrated on the chest CT?
A. Left pleural effusion
B. Right pneumothorax
C. Bilateral consolidation
D. Pulmonary embolism
Answer: B. The CT demonstrates a large right pneumothorax.
Question 4
Which statement best describes the diagnostic role of AI in this type of case?
A. AI can replace radiologist interpretation
B. AI eliminates the need for clinical correlation
C. AI may provide detection or second-reader support but requires human verification
D. AI can establish the final diagnosis without considering extrapulmonary findings
Answer: C. AI can potentially support detection and prioritization, but diagnostic responsibility remains with the clinician.
Key Takeaways
Lymphangioleiomyomatosis should be considered when a woman presents with pneumothorax and CT demonstrates diffuse bilateral pulmonary cysts.
The most important imaging clue is the presence of numerous small, round, thin-walled cysts distributed throughout both lungs.
The renal angiomyolipoma in this case provides an additional extrapulmonary clue supporting the diagnosis.
The major radiologic lesson is not simply to identify the pneumothorax, but to identify the underlying lung pattern that explains why the pneumothorax occurred.
For radiologists, systematically reviewing the entire examination remains essential even when an obvious emergency finding has already been identified.
For AI-enabled imaging workflows, the case illustrates both an opportunity and a limitation: AI may help detect individual findings, but integrating findings across organs, modalities, and clinical context remains a more complex reasoning task.
Continue Learning
Differential Diagnosis of Diffuse Cystic Lung Disease on CT
[INTERNAL LINK PLACEHOLDER]How to Recognize Birt-Hogg-Dubé Syndrome on Chest CT
[INTERNAL LINK PLACEHOLDER]Pulmonary Langerhans Cell Histiocytosis: CT Findings and Diagnostic Clues
[INTERNAL LINK PLACEHOLDER]Renal Angiomyolipoma on Ultrasound and CT
[INTERNAL LINK PLACEHOLDER]AI Detection of Pneumothorax on Chest CT and Radiographs
[INTERNAL LINK PLACEHOLDER]
References
[1] G. F. Abbott, M. L. Rosado-de-Christenson, A. A. Frazier, T. J. Franks, R. D. Pugatch, and J. R. Galvin, “Lymphangioleiomyomatosis: Radiologic-pathologic correlation,” RadioGraphics, vol. 25, no. 3, pp. 803–828, 2005, doi: 10.1148/rg.253055006.
[2] N. A. Avila, A. J. Dwyer, and J. Moss, “Imaging features of lymphangioleiomyomatosis: Diagnostic pitfalls,” American Journal of Roentgenology, vol. 196, no. 4, pp. 982–986, 2011, doi: 10.2214/AJR.10.4185.
[3] S. Niku, P. Stark, D. L. Levin, and P. J. Friedman, “Lymphangioleiomyomatosis: Clinical, pathologic, and radiologic manifestations,” Journal of Thoracic Imaging, vol. 20, no. 2, pp. 98–102, 2005, doi: 10.1097/01.rti.0000154071.31873.e2.
[4] F. X. McCormack, “Lymphangioleiomyomatosis: A clinical update,” Chest, vol. 133, no. 2, pp. 507–516, 2008, doi: 10.1378/chest.07-0898.
[5] S. R. Johnson et al., “European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis,” European Respiratory Journal, vol. 35, no. 1, pp. 14–26, 2010, doi: 10.1183/09031936.00076209.
[6] F. X. McCormack et al., “Official American Thoracic Society/Japanese Respiratory Society clinical practice guidelines: Lymphangioleiomyomatosis diagnosis and management,” American Journal of Respiratory and Critical Care Medicine, vol. 194, no. 6, pp. 748–761, 2016, doi: 10.1164/rccm.201607-1384ST.
[7] N. Gupta et al., “Lymphangioleiomyomatosis diagnosis and management: High-resolution chest computed tomography, transbronchial lung biopsy, and pleural disease management. An official American Thoracic Society/Japanese Respiratory Society clinical practice guideline,” American Journal of Respiratory and Critical Care Medicine, vol. 196, no. 10, pp. 1337–1348, 2017, doi: 10.1164/rccm.201709-1965ST.
[8] L. R. Young, Y. Inoue, and F. X. McCormack, “Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis,” New England Journal of Medicine, vol. 358, no. 2, pp. 199–200, 2008, doi: 10.1056/NEJMc0707517.
[9] F. X. McCormack et al., “Efficacy and safety of sirolimus in lymphangioleiomyomatosis,” New England Journal of Medicine, vol. 364, no. 17, pp. 1595–1606, 2011, doi: 10.1056/NEJMoa1100391.
[10] A. M. O’Mahony, E. Lynn, D. J. Murphy, A. Fabre, and C. McCarthy, “Lymphangioleiomyomatosis: A clinical review,” Breathe, vol. 16, no. 2, Art. no. 200007, 2020, doi: 10.1183/20734735.0007-2020.
Medical Disclaimer
Comments
Post a Comment